Inventor

SELBY MARK J

US62 patents

⚠️ This page may combine multiple inventors who share the name “SELBY MARK J”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

SELBY MARK J

BRISTOL MYERS SQUIBB CO

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Anti-ICOS agonist antibodies and uses thereof

Ipilimumab variant with enhanced ADCC

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Antibodies comprising modified heavy constant regions

Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors

Anti-ICOS agonist antibodies and uses thereof

Anti-ICOS agonist antibodies and uses thereof

Antibodies against TIM3 and uses thereof

Anti-ICOS agonist antibodies and uses thereof

Antibodies against TIM3 and uses thereof

Antibodies against TIM3 and uses thereof

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Antibodies against TIM3 and uses thereof

Anti-GITR antibodies for cancer diagnostics

Anti-CD27 antibodies and uses thereof

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

Anti-ICOS agonist antibodies and uses thereof

SQUIBB & SONS LLC

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

Methods for treating cancer using anti-PD-1 antibodies

Monoclonal antibodies to Programmed Death 1 (PD-1)

Monoclonal antibodies to programmed death 1 (PD-1)

Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation Gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Monoclonal antibodies to programmed death 1 (PD-1)

Human monoclonal antibodies to O8E

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Human antibodies that bind lymphocyte activation gene-3 (LAG-3), and uses thereof

Human antibodies that bind Lymphocyte Activation Gene-3 (LAG-3), and uses thereof

MEDAREX INC

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)

Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

MEDAREX LLC

Methods for treating cancer using anti-PD-1 antibodies

Fully human antibodies to BTLA

KORMAN ALAN J

Monoclonal antibodies to programmed death 1 (PD-1)

Human monoclonal antibodies to O8E

CHIRON CORP

Methods and compositions for controlling translation of HCV proteins

Methods and compositions for controlling translation of HCV proteins